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Abstract
 
Regulatory CD4 T cells (Treg) control inflammatory reactions to commensal bacteria and
opportunist pathogens. Activation of Treg functions during these processes might be mediated
by host-derived proinflammatory molecules or directly by bacterial products. We tested the
hypothesis that engagement of germline-encoded receptors expressed by Treg participate in the
triggering of their function. We report that the subset of CD4 cells known to exert regulatory
functions in vivo (CD45RB
 
low 
 
CD25
 

 
) selectively express Toll-like receptors (TLR)-4, -5, -7,
and -8. Exposure of CD4
 
 
 
CD25
 
 
 
cells to the TLR-4 ligand lipopolysaccharide (LPS) induces
up-regulation of several activation markers and enhances their survival/proliferation. This pro-
liferative response does not require antigen-presenting cells and is augmented by T cell recep-
tor triggering and interleukin 2 stimulation. Most importantly, LPS treatment increases CD4
 

 
CD25
 
 
 
cell suppressor efficiency by 10-fold and reveals suppressive activity in the CD4
 

 
CD45RB
 
low 
 
CD25
 
 
 
subset that when tested ex-vivo, scores negative. Moreover, LPS-activated
Treg efficiently control naive CD4 T cell–dependent wasting disease. These findings provide
the first evidence that Treg respond directly to proinflammatory bacterial products, a mecha-
nism that likely contributes to the control of inflammatory responses.
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Introduction
 
It is established that a subpopulation of CD4-
 
 
 
T cells
controls inflammatory responses to commensal bacteria and
pathogens (1–4). These cells are encompassed in the natu-
rally activated lymphocytes (CD45RB
 
low
 
) and enriched in
the CD25-expressing subset. In the absence of regulatory T
 
cells (Treg),
 
*
 
 alymphoid animals reconstituted with CD4
cells isolated from normal mice develop severe inflamma-
tory bowel disease if colonized by enteric bacteria (1), or
lethal pneumonia if infected by 
 
Pneumocystis carinii
 
 (2).
Cotransfers of Treg protect from disease by inhibiting both
the protective (2) and inflammatory responses (1, 2), lead-
ing to the notion of “quality control” of the immune re-
sponse (for review see reference 5).
These activities of Treg suggest their engagement at early
stages of infection/inflammation. Accordingly, evidence
exists for rapid Treg migration to inflammatory sites, likely
as a result of the constitutive expression of chemokine re-
ceptors (6) and high sensitivity to inflammatory chemo-
kines (7). Once at the site of infection, however, it remains
unclear whether activation of Treg function is triggered by
components of the host inflammatory response or by direct
recognition of microbial products. In either case, engage-
ment of germline-encoded receptors is an attractive possi-
bility. Toll-like receptors (TLRs) ensure vertebrates with
the means to recognize a vast range of microbial products
and produce immediate, “innate” responses. Thus, TLRs
expressed in B lymphocytes trigger effector functions such
as antibody production, providing a direct link between
innate and adaptive immunity (8, 9). Furthermore, endog-
enous molecules such as heat shock proteins (HSP; refer-
ences 10–13) or oligosaccharides of hyaluronan (14) have
recently been shown to functionally ligate TLR-4 in mac-
 
rophages or dendritic cells, and may participate in inflamma-
tory reactions. On the other hand, although TLR-4 ex-
pression in murine CD3
 
 
 
lymphocytes (15) and more
specifically in particular subsets of 
 
 
 
T cells (16) has been
reported, expression of TLR genes in CD4-
 
 
 
T cell sub-
populations has not been directly assessed.
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de Ciência, Rua da Quinta Grande #6, Apartado 14, 2781-901 Oeiras,
Portugal. Phone: 351-21-440-7908; Fax: 351-21-440-7970; E-mail:
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*
 
Abbreviations used in this paper:
 
 HSP, heat shock proteins; I
 
50%
 
, 50% in-
hibition; TLR, Toll-like receptor; Treg, regulatory T cells.
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LPS Directly Activates Regulatory T Cells
 
In these experiments, we directly tested whether proin-
flammatory microbial products activate CD4 cells involved
in the control of inflammatory reactions. We first moni-
tored the expression profile of all nine murine TLR genes
thus far identified in various subsets of CD4 T cells. The
results show that TLR-4, -5, -7, and -8 are selectively ex-
pressed in CD4 T cell subsets that contain Treg. We then
established that CD4
 
 
 
CD25
 
 
 
cells, unresponsive to TCR
triggering, are activated and proliferate when treated with
the TLR-4 ligand LPS. This proliferative response does not
require APC, is augmented by TCR triggering, and syner-
gizes with IL-2 stimulation. Finally, we show that exposure
to LPS markedly increases Treg activity as measured in
suppression assays in vitro and maintains their regulatory
function in vivo.
 
Materials and Methods
 
Mice
 
All animals were bred and maintained under specific pathogen-
free conditions in our animal facilities. C57BL/6 and C57BL/6-
 
Thy1.1
 
 mice were originally purchased from The Jackson Labo-
ratory. C57BL/10ScCr mice (B10ScCr) were obtained from
CDTA. C3H/HeJ and C3H/HeN were purchased from The
Jackson Laboratory. C57BL/6-
 
H-2
 
u 
 
and RAG-1
 

 
/
 
 
 
animals were
provided by S. Tonegawa, MIT, Boston, MA. C57Bl-
 
H-2
 
u
 
Thy1
 
a 
 
mice have been previously described (17). All animals used
in this study were 6–8 wk old.
 
Cell Purification
 
Erythrocyte-depleted splenocytes and LN cells were prepared
as previously described (17). For flow cytometry purification of
CD4
 
 
 
cell subsets, pooled LN cells were stained with Cy-
Chrome-conjugated CD4 mAb (clone RMA-5; BD Bio-
sciences), Alexa Fluor™ 488-CD25 (PC61; produced in the lab-
oratory), and CD45RB-PE (clone 16A; BD Biosciences). In
some experiments, the following mAbs were pooled and used in
addition to exclude nonconventional CD4 cells: B220-PE (RA3-
6B2), CD11c-PE (clone HL3), PanNK-PE (DX-5), Mac I biotin
(clone M1/70), and MHC-II biotin (clone M5-114; all from BD
Biosciences). Biotinylated Abs were revealed with PE-labeled
Streptavidin (BD Biosciences). The reference B cell population
was sort-purified after staining with CD19-FITC (clone 1D3; BD
Biosciences). Cell sorting was performed on a MoFlo
 
® 
 
high speed
cellsorter (DakoCytomation). The purity of each cell preparation
was 
 

 
97%. CD4
 
 
 
contaminants in the CD4
 
 
 
CD25
 
 
 
prepara-
tions represented routinely 0.5%. CD4
 
 
 
CD25
 
 
 
cells used in the
suppression assays were prepared by magnetic purification. Total
LN and erythrocyte-lysed splenocytes were first depleted of
CD25
 
 
 
cells by treatment with 7D4 mAb (produced in the labo-
ratory) and complement (low-tox rabbit complement; Cedar-
lane). Cells were then stained with anti-CD4 (L3T4) microbeads
and positively separated on LS
 
 
 
columns (both from Miltenyi
Biotec). Erythrocyte-depleted splenocytes, treated with J1J anti-
Thy1 mAb (produced in the laboratory) and complement, were
irradiated at 30 Gy and used as a source of APC. Additional anti-
bodies used for FACS
 
® 
 
analyses were: class I (H2Kb AF6-88.5)
and B.7 (16-10A1), CD69 (H1.2F3), CD44 (IM7), CD38 (90),
TCR
 

 
 (H57-597), Thy1.1 (OX-7), and Thy1.2 (53-2.1; all from
BD Biosciences). FACS
 
® 
 
analyses were performed on a FACS-
 
Calibur
 
® 
 
instrument run with the CellQuest™ program (both
from Becton Dickinson). Dead cells were gated out after propid-
ium iodide staining.
 
RT-PCR Reactions
 
Total RNA was extracted from 10
 
6 
 
cells using Trizol reagent,
treated with DNase I and reverse transcribed using Superscript II
RT and oligo(dT)
 
12–18 
 
primer (all four reagents from Life Tech-
nologies). The amount of cDNA in each sample was first normal-
ized after nonsaturating PCR for HPRT transcripts. 25 
 
	
 
l reac-
tion mixture contained 1.5 mM MgCl
 
2
 
, 0.2 mM dNTP, 25 pmol
sense and antisense primer (5
 


 
-GTAATGATCGTCAACGGGG-
GAC and 5
 


 
-CCAGCAAGCTTGCAACCTTAACCA), and 1 U
Taq DNA polymerase (Life Technologies) in the manufacturer’s
buffer. PCR consisted of 5 min at 94
 

 
C followed by 26 cycles of
30 s at 94
 

 
C, 55
 

 
C, and 72
 

 
C, terminated by 10 min at 72
 

 
C.
The specific TLR primer sequences and their respective anneal-
ing temperatures are shown in Table I. Other conditions were as
described above except for 35 cycles. Reactions were not satu-
rated as controlled by increasing the amount of template (not de-
picted). All PCRs were performed on a PTC-100™ programma-
ble thermal controller (MJ Research Inc.). After separation on 2%
agarose gels containing ethidium bromide (Sigma-Aldrich), the
specific bands were quantified with an Eagle Eye
 
® 
 
II still video
system (Stratagene).
 
Cell Cultures and Proliferation Assays
 
All cultures were set in RPMI-1640 supplemented with 10%
FCS, 100 U/ml penicillin, 100 
 
	
 
g/ml streptomycin, 50 
 
	
 
g/ml
 
Table I.
 
Primer Sequences for Mouse TLR RT-PCR Used in 
This Study
 
Nucleic sequences
 
a
 
Tp
 
b
 
TLR-1 TCTCTGAAGGCTTTGTCGATACA 56
GACAGAGCCTGTAAGCATATTCG
TLR-2 TCTAAAGTCGATCCGCGACAT 58
TACCCAGCTCGCTCACTACGT
TLR-3 TTGTCTTCTGCACGAACCTG 58
CGCAACGCAAGGATTTTATT
TLR-4 CAAGAACATAGATCTGAGCTTCAACCC 62
GCTGTCCAATAGGGAAGCTTTCTAGAG
TLR-5 ACTGAATTCCTTAAGCGACGTA 56
AGAAGATAAAGCCGTGCGAAA
TLR-6 AACAGGATACGGAGCCTTGA 58
CCAGGAAAGTCAGCTTCGTC
TLR-7 TTCCGATACGATGAATATGCACG 56
TGAGTTTGTCCAGAAGCCGTAAT
TLR-8 GGCACAACTCCCTTGTGATT 58
CATTTGGGTGCTGTTGTTTG
TLR-9
 
c
 
CCGCAAGACTCTATTTGTGCTGG 62
TGTCCCTAGTCAGGGCTGTACTCAG
 
a
 
Sequences are written 5
 

 
 
to 3
 


 
, sense and antisense primers successively.
 
b
 
Annealing temperature in 
 

 
C.
 
c
 
Reference 48.
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 
405
 
Caramalho et al.
 
gentamycin, 50 
 
	
 
M 2
 

 
-ME, 10 mM Hepes, and 1 mM sodium
pyruvate (all from Life Technologies).
For PCR controls, sort-purified CD4
 
 
 
CD25
 
 
 
CD45RB
 
high
 
(10
 
6
 
/well in 24-well plates) were stimulated for 3 d with 1 
 
	
 
g/
ml plate-bound anti-CD3 mAb (145.2C11; produced in the
laboratory) and 1 
 
	
 
g/ml soluble anti-CD28 mAb (clone 37.51;
BD Biosciences).
 
LPS-induced Proliferation.
 
Cultures were set in triplicates in
96-well plates maintained for 3 d at 37
 

 
C, 5% CO2. Each well
contained 2.5 
 
 
 
10
 
4 
 
purified CD4
 
 
 
cells with or without 5 
 

 
10
 
4 
 
APC, 0.5 ug/ml anti-CD3 mAb, IL-2 from X63-IL2 cell su-
pernatant (
 

 
10 U/ml) diluted at 1/500, and 10 
 
	
 
g/ml LPS
from 
 
Salmonella typhymurium
 
 (Sigma-Aldrich). In experiments
comparing cells purified from WT, B10ScCr, and C3H/HeJ an-
imals, LPS from 
 
Escherichia coli
 
 EH100 was HPLC purified (pro-
vided by C. Galanos, Max-Planck Institute for Immunobiology,
Freiburg, Germany).
 
IL-2 Production.
 
Primary cultures were set in triplicate in 96-
well plates containing 100 
 
	
 
l medium. After 48 (CD4
 
 
 
CD25
 

 
cells) or 72 (CD4
 
 
 
CD25
 
 
 
cells) h, 50 
 
	
 
l of the supernatant was
transferred to a new well containing 1,000 CTLL-2 cells and 50
 
	
 
l fresh medium. Amplification of the response was achieved 48 h
later by adding saturating IL-2 (as described above) for 24 h.
 
LPS Pretreatments.
 
Sort-purified CD4
 
 
 
subpopulations (1.5–2 
 

 
10
 
6
 
/well) were seeded in 24-well plates for 3 d in the presence of
10 
 
	
 
g/ml LPS (Sigma-Aldrich) with or without 1 
 
	
 
g/ml soluble
or plate-bound anti-CD3 mAb. In some experiments, after wash-
ing in media, cells were cultured for an additional 3 d in the pres-
ence of IL-2 and 1 
 
	
 
g/ml soluble anti-CD3 mAb. To assess the
induction of surface molecules, erythrocyte-lysed splenocytes
were plated at 1.5 
 
 
 
10
 
6
 
/ml in medium alone or supplemented
with 10 
 
	
 
g/ml LPS (Sigma-Aldrich) for 18 h.
 
Suppression Assay.
 
CD4
 
 
 
CD25
 
 
 
cells (target cells) were
plated at 2.5 
 
 
 
10
 
4
 
/well in U-shape 96-well plates together with
10
 
5 
 
APC and 0.5 
 
	
 
g/ml anti-CD3 mAb and variable numbers of
the suppressor populations under test. Each dilution was set in
triplicate and culture was maintained for 3 d. All proliferations
were monitored by addition of [
 
3
 
H]thymidine (1 
 
	
 
Ci/well; Am-
ersham Biosciences) for the last 6 h of culture.
 
Adoptive Transfer
 
Pooled LN from C57BL-
 
H-2
 
u 
 
Thy1.2
 
 and C57BL-
 
H-2
 
u
 
Thy1.1 mice were used to sort purify CD4 CD25 and CD4
CD25 cells, respectively. C57BL-H-2u RAG-1/ recipients
were injected intravenously at 8 wk of age. Weight and general
health status was monitored every 3 d for 21 d.
Results
Selective Expression of TLR-4, -5, -7, and -8 by Treg.
LN lymphocytes were FACS® purified under highly strin-
gent gate definitions according to the CD4 and CD45RB
surface markers and TLR-4 expression was assessed in the
various subsets by RT-PCR in nonsaturating conditions.
Naive CD4 cells (CD45RBhigh) scored negative whereas
the samples of activated/memory CD45RBlow cells pre-
pared in parallel displayed a clear signal (Fig. 1 a). Addi-
tional fractionation of the CD4 CD45RBlow subset ac-
cording to the expression of the CD25 molecule revealed
the heterogeneity of this population. The RT-PCR signal
was reproducibly three- to fourfold higher in the CD25
compared with the CD25 subset (Fig. 1 b). The PCR
product obtained in either CD45RBlow population was
cloned and sequenced to confirm its identity with the pub-
lished TLR-4 sequence (not depicted). Expression of
TLR-4 by CD4 cells is not merely the result of activation
because naive CD4 cells (CD45RBhigh CD25) activated
in culture for 3 d using plate-bound anti-CD3 together
with anti-CD28 acquire a CD45RBlow CD25 phenotype
(not depicted), but continue to score negative for TLR-4
expression in the RT-PCR assay (Fig. 1 b). Finally, analy-
ses of CD4 cells in various lymphoid tissues (thymus, me-
senteric LN, axillary LN, and spleen) revealed preferential
expression of TLR-4 in CD4 CD25 cells independently
of their location, although more marked in cells purified
from the spleen (Fig. 1 c). Therefore, TLR-4 expression in
CD4 T cell subsets is restricted to subpopulations with
known in vivo regulatory functions and may represent a
specific marker for Treg differentiation.
These results prompted us to monitor the expression of
all identified murine TLR genes in the same CD4 T cell
subsets. As shown in Fig. 1 c, three additional TLRs (TLR-5,
-7, and -8) were found preferentially expressed by CD4
CD45RBlow cells. TLR-5 expression was undetectable in B
and naive CD4 T cells and, similarly to TLR-4, markedly
increased in the CD25 subset when compared with
CD45RBlow CD25 cells (fourfold). TLR-7 transcripts
were detectable in naive CD4 cells albeit to a lower level
than in the naturally activated subset of CD4 cells (four-
fold and twofold, respectively, when compared with
CD45RBlow CD25 and CD25). Finally, TLR-8 ap-
Figure 1. Specific expression of TLR genes by Treg. RNA from sort-
purified CD19 (B cells) and various subpopulations of CD4 cells (4)
from B6 mice, either pooled LNs (a, b, and d) or specific lymphoid or-
gans (c) were submitted to RT-PCR. CD4 CD45RBlow or CD4
CD45RBhigh (4 45RBlow or 4 45RBhigh) were sorted as negative for
CD11c, CD11b, B220, pan-NK, and MHC II in addition to positive for
CD4 and CD45RB (a) or simply according to CD4, CD45RB, and
CD25 expression (b, c, and d). Erythrocyte-lysed splenocytes from B6 or
TLR-4–deficient B10ScCr animals and in vitro–activated B6 CD4
CD45RBhigh served as controls. All RT-PCR were performed at least
twice on independent samples.
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peared specifically expressed in the CD4 CD45RBlow
compartment independently of its CD25 phenotype. Simi-
larly to TLR-4, expression of these genes was not induced
by in vitro activation of purified naive CD4 T cells (not
depicted). Less relevant for this study but noteworthy in
the interplay of innate and adaptive immunity, expression
of TLR-1, -2, and -6 was readily detectable in all CD4
cell populations analyzed. Finally, expression of both TLR-3
and TLR-9 was clearly detectable in total splenocytes but
not significantly in any of the CD4 T cell subsets.
LPS Treatment Induces the Expression of Several Activation
Markers on CD4 CD25 T Cells. Next, we investigated
whether the expression of TLR-4 by CD4 CD45RBlow
CD25 cells was functionally relevant, i.e., if such cells re-
sponded to LPS, the classical TLR-4 ligand for B cells and
macrophages (18). In a first step, we performed FACS®
analyses of splenocytes treated for 18 h with LPS in vitro.
As shown in Fig. 2, CD4 CD25 cells, similarly to mac-
rophages and B lymphocytes, up-regulate the expression of
Class I, CD69, and B7.1 surface molecules. In addition, ex-
pression of other T cell–specific activation markers (CD44
and CD38) were also significantly enhanced whereas the
levels of TCR expression were not affected. In contrast,
expression of CTLA-4, cytoplasmic IL-10, and TNF- re-
mained unaltered upon exposure to LPS (not depicted). Fi-
nally, CD4 CD25 cells failed to up-regulate any of these
molecules when exposed to LPS in the same conditions.
Up-regulation of CD69 expression by T cells upon expo-
sure to LPS in vitro has been previously described (19) and
is a response we attribute to CD4 CD25 cells. A previous
report also described the induction of B7 expression on
CD4 CD25 cells upon TCR triggering (20), a finding
that we now extend to LPS activation.
LPS Directly Induces CD4 CD25 Cell Survival/Prolifera-
tion. Previous studies indicate that LPS stimulation of B
cells in vitro enhances their survival (21, 22). Similarly, sur-
vival of purified CD4 CD25 cells maintained in culture
was greatly enhanced by the addition of LPS. Thus, al-
though the number of cells recovered after a 3-d culture in
medium supplemented or not with anti-CD3 antibody
represented routinely 1–2% of the initial number of seeded
cells, these values reached 15% in cultures containing
anti-CD3 antibody and LPS or IL-2 and 30% when me-
dia was supplemented with both LPS and IL-2. In 6-d cul-
tures containing anti-CD3 and IL-2, the addition of LPS
for the first 3 d enhanced the cell recoveries from 32 to
62% (not depicted). These observations confirm that exo-
crine IL-2 acts as a survival/growth factor for CD4
CD25 cells (23) and demonstrates similar effects for LPS.
Because LPS is a potent B lymphocyte mitogen, we also
tested its effect on CD4 CD25 proliferation. As reported
(24, 25), highly purified CD4 CD25 cells do not prolif-
erate in APC-supplemented cultures in response to TCR
ligation whereas they do expand in the presence of IL-2.
The addition of LPS to otherwise unresponsive cultures
containing anti-CD3 antibodies and APC induced a readily
detectable incorporation of [3H]thymidine that was consis-
tently 20-fold higher than in controls, although 5-fold
lower than IL-2–induced responses (Fig. 3 a). The removal
of APC from these cultures resulted in higher [3H]thymi-
dine incorporation in response to LPS while reducing the
IL-2–mediated response. The responses of CD4 CD25
cells to LPS are also detectable in the absence of TCR trig-
gering, albeit to a much lower level (Fig. 3 b, note the dif-
ferent scale). Interestingly, in the absence of both APC and
anti-CD3 antibodies, responses to LPS scored higher than
those to IL-2. Assessing the dose response of CD4 CD25
to LPS treatment (Fig. 3 c) reveals a peak of proliferation at
10 	g/ml, a result similar to what is routinely obtained
when testing B lymphocytes (not depicted). This dose is
much higher than that required to induce maximal re-
sponses in components of the innate immune system like
dendritic cells and macrophages (in the order of nano-
grams). Contrary with B cell responses to LPS and anti-
BCR (26), proliferation of CD4 CD25 is increased by
the addition of anti-CD3 independently of the dose of
LPS. These results indicate that LPS treatment induces
TCR triggering sensitivity whereas TCR engagement does
not affect the sensitivity to LPS.
To directly assess whether LPS induces proliferation of
CD4 CD25 cells through engagement of the TLR-4 re-
ceptor, we tested cells from LPS nonresponder and re-
sponder animals (27). In similar cultures to those described
above, CD4 CD25 cells purified from TLR-4–deficient
B10ScCr or C3H/HeJ (28, 29) mice did not respond to
LPS (Fig. 3, d and e) regardless of the presence of APC or
anti-CD3 (not depicted), but they did respond to IL-2.
Furthermore, the LPS and IL-2 effects are additive in B6
animals but not in the B10ScCr T cells. Finally, using ei-
ther B6 or B10ScCr APC altered neither the LPS response
of B6 CD4 CD25 cells nor the unresponsiveness of
TLR-4–deficient CD4 CD25 cells (not depicted), con-
firming that such T cell responses are not mediated by LPS
activation of APC.
Taken together, these results demonstrate that LPS di-
rectly activates survival/proliferation of CD4 CD25 T
cells through the TLR-4 receptor molecule.
TCR Triggering of LPS-activated CD4 CD25 Cells In-
duces IL-2 Production. The inability of CD4 CD25 cells
to engage in cycle upon TCR triggering has been attributed
Figure 2. Activation of CD4
CD25 cells upon LPS treat-
ment of splenocytes in vitro.
Erythrocyte-depleted spleno-
cytes were cultured for 18 h in
the presence of LPS (bold) or
medium alone (plain) and stained
for CD4, CD25, and various
other surface molecules. Histo-
grams correspond to FACS®
analyses for the indicated mole-
cules inside the three indepen-
dent gates. Representative analy-
sis out of four independent
assessments is shown. A mini-
mum of 5,000 events was ac-
quired in the CD4 CD25 gate.
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to their incapacity to produce IL-2 (24, 25). We described
above that upon LPS stimulation, CD4 CD25 cells re-
spond to TCR triggering by increased proliferation. This re-
sult may indicate that LPS induces endogenous IL-2 produc-
tion. To directly address this point, we developed a highly
sensitive assay to detect IL-2 produced by cells maintained in
culture. As shown in Fig. 4 a, supernatants from 1,000 naive
CD4 cells stimulated for 48 h in presence of APC and anti-
CD3 induce readily detectable proliferation of the IL-2–
dependent CTLL-2 cell line. This proliferation is propor-
tional to the number of CD4 cells seeded. When testing the
supernatants from 2.105 CD4 CD25 cells maintained in
culture for 3 d in the presence of LPS, IL-2 production was
undetectable (Fig. 4 b). However, similar cultures supple-
mented with anti-CD3 provided enough IL-2 to induce de-
tectable proliferation of the CTLL-2 cells. Moreover, pro-
duction of IL-2 was markedly enhanced when anti-CD3
was provided plate bound instead of soluble.
These results indicate that LPS per se does not induce
endogenous IL-2 production. However, it seems to confer
sensitivity to TCR triggering, a signal that in turn leads to a
low level of IL-2 synthesis.
Exposure of CD45RBlow CD25 or CD45RBlow CD25 T
Cells to LPS Markedly Enhances Their Suppressive Func-
tions. Next, we investigated whether LPS affects the ef-
fector functions of CD4 CD25 cells. Currently, the abil-
ity of CD4 CD25 cells to suppress the proliferative
response of naive CD4 T cells to TCR triggering in the
presence of APC is used as an in vitro correlate of their reg-
ulatory function in vivo (24, 25). According to the obser-
vations described above on LPS-induced survival/prolifera-
tion, we tested cells that were first differentially exposed to
LPS for 3 d and then provided with IL-2 for an additional
3-d period. The inhibition of CD4 CD25 proliferation is
plotted in Fig. 5 as a function of the ratio of “regulatory” to
target cells. The ratio corresponding to a 50% inhibition
(I50%) can serve as an index of suppression efficiency. The
I50% of freshly isolated CD4 CD25 cells was 0.25 (i.e.,
one regulatory to four target cells) in several independent
experiments. As shown in Fig. 5 a, culturing this cell popu-
lation for 6 d with IL-2 (and anti-CD3) improved the I50%
to 0.07 (1 to 14), a result consistent with previous findings
(30). In the same conditions, however, exposure to LPS for
the first 3 d resulted in even higher levels of suppressive ac-
tivity, as indicated by an I50% lower than 0.025, the last
point in our titrations (1 to 40). We also tested CD4
CD25 cells that were pretreated with LPS in the absence
or presence of plate-bound anti-CD3 antibodies. Indepen-
dently of the presence of anti-CD3, the I50% was consis-
tently fourfold higher when cells had been exposed succes-
sively to LPS and IL-2, as compared with IL-2 alone (not
depicted). These results demonstrate LPS-dependent acti-
vation of effector functions in CD4 CD25 cells.
CD4 CD45RBlow CD25 cells exert regulatory func-
tions in vivo (31), but do not show suppressor activity in
vitro when freshly isolated (Fig. 5 b and reference 24).
Strikingly, however, CD4 CD45RBlow CD25 cells man-
ifested a remarkable I50% of 0.1 (1 to 10) after in vitro ex-
Figure 3. LPS directly induces CD4 CD25
proliferation through TLR-4. (a and b) Prolifera-
tive responses of CD4 CD25 cells to LPS are
APC independent. Sort-purified CD4 CD25
from B6 animals were maintained in culture for 3 d
in the presence of anti-CD3 (a) or not (b) and
supplemented or not with APC (solid or open
bars). For each culture condition, proliferative re-
sponses induced by either LPS or IL-2 are com-
pared. (c) Purified CD4 CD25 cells were cul-
tured for 3 d in the absence of APC in medium
supplemented with various doses of LPS. (d and e)
TLR-4–deficient CD4 CD25 cells do not prolif-
erate in response to LPS. CD4 CD25 were sort
purified from TLR-4–competent animals B6 (d)
and C3H/HeN (e; open bars) or TLR-4–deficient
B10ScCr (d) and C3H/HeJ (e) mice (solid bars)
and maintained for 3 d in culture without APC nor
anti-CD3. The medium was supplemented with
LPS, IL-2, or both, as indicated. Each assay has
been performed at least twice on independent cell
samples and with similar results.
Figure 4. IL-2 production by
CD4 CD25 cells upon LPS
stimulation. (a) Sensitivity of the
assay. Supernatant of various
numbers of CD4 CD25 cells
cultured for 48 h in the presence
of APC and anti-CD3 were used
as a source of IL-2 to support
CTLL-2 cell proliferation. Pro-
liferation of CTLL-2 cells in the
absence of supernatant (alone) or
when they were provided with
saturating amount of IL-2 (IL-2)
are shown. (b) CTLL-2 prolifer-
ation induced by supernatants of
2.105 CD4 CD25 cells main-
tained in culture for 3 d in the
presence of LPS and anti-CD3 as
indicated. Background proliferation is shown on the left. Each assay has
been performed twice, each in triplicates.
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posure to LPS followed by IL-2 (Fig. 5 b). As titration
curves for cells exposed sequentially to LPS and IL-2 or to
IL-2 alone were similar, we also tested CD4 CD45RBlow
CD25 cells immediately after 3 d of LPS activation. As
can be seen in Fig. 5 c, LPS clearly promotes suppressive
activity in this cell population. CD4 CD25 similarly ex-
posed for 3 d to LPS without subsequent exposure to IL-2
showed lower suppressor efficiency than untreated cells.
This result is best explained by the poor survival of CD4
CD25 cells in absence of exogenous IL-2 (as described
above), preventing a proper evaluation of suppressor effi-
ciency on a per cell basis. This argument is supported by
our results above, which show that when subsequently
provided with IL-2, the same cell population displays max-
imal suppressor efficiency. Finally, as expected, CD4
CD45RBhigh cells stimulated for 6 d in cultures supple-
mented with IL-2 and soluble anti-CD3 did not show any
suppressor activity, regardless of their differential exposure
to LPS for the first 3 d of culture (not depicted).
We conclude that LPS markedly enhances the suppres-
sive activity of naturally activated CD45RBlow T cells,
whether these are CD25 or CD25.
LPS-activated CD4 CD25 T Cells Prevent Wasting Dis-
ease Induced by Naive CD4 T Cells in Alymphoid Recipi-
ents. To assess whether the suppressive function we mon-
itored in vitro correlates with in vivo regulatory functions,
we tested the ability of LPS-treated CD4 CD25 cells to
control the wasting disease that is induced in RAG-defi-
cient animals upon transfer of naive CD4 cells (1). C57BL/
6-H-2u RAG-1/ recipients of CD4 CD45RBhigh
(Thy1.2) cells developed a lethal wasting disease in less
than 3 wk after adoptive transfer. This extremely fast devel-
opment associated neither with pathological intestinal in-
flammation nor pneumonia, contrarily to what is observed
in other genetic backgrounds (1, 2). Animals that received
CD4 CD25 (Thy1.1), either freshly isolated or exposed
to LPS followed by IL-2, remained healthy (Fig. 6 a). In
addition, cotransfer with either population of CD4
CD25 cells reduced the number of transferred naive
Thy1.2 lymphocytes recovered from mesenteric LNs (Fig.
6 b), spleen and pooled axillary and cervical LNs (not de-
picted) to a similar extent. Finally, the numbers of trans-
ferred CD4 CD25 cells recovered in recipients of the
cotransfers were similar in the two groups of animals as
were their respective levels of CD25 expression (exempli-
fied in Fig. 6 c).
These results demonstrate efficient control of inflamma-
tion and homeostatic expansion by LPS activated CD4
CD25 cells in vivo.
Discussion
Here we provide the first evidence for the selective ex-
pression of pathogen-associated “pattern recognition recep-
tors” by Treg and the functional relevance of one of them,
TLR-4, in the physiology of this cell subpopulation. Our
findings that LPS promotes Treg survival/proliferation and
enhances their suppressive functions also demonstrate that
T cells involved in the control of inflammation directly re-
spond to proinflammatory microbial products. Thus, this
analysis provides another link between innate and adaptive
immunity and reveals a novel mechanism for the control of
immune responses.
The rather high proportion of TLR genes, classical com-
ponents of the innate immune system, selectively expressed
in a subset of CD4 cells endowed with the function of reg-
ulating adaptive immune responses, may help us delineate
the evolutionary scheme that led to the establishment of an
adaptive immune system. Among the nine known murine
TLR genes analyzed here, four (TLR-4, -5, -7, and -8) are
selectively expressed in this particular CD4 subset. TLR-5
expression appeared the most selective for Treg. In line
Figure 5. LPS treatment enhances the suppressor func-
tion of Treg. (a) Suppressor efficiency of CD4 CD25 is
greatly enhanced upon exposure to LPS. Sort-purified
CD4 CD25 T cells were maintained in culture in me-
dium supplemented with anti-CD3 and either LPS for 3 d
followed by 3 d with IL-2 (LPS/IL-2) or with IL-2 for 6 d
(IL-2). The same cell population not submitted to culture
was used as reference control (fresh). Proliferation of
CD4 CD25 stimulated with anti-CD3 and APC in the
presence of increasing numbers of these CD4 CD25 cells
was monitored on day 3. The percent of inhibition ([cpm
in control  cpm in experiment]/cpm in control) is plotted
versus the ratio of CD4 CD25/CD4CD25 cell num-
ber at the origin of the culture. (b and c) LPS treatment of
CD4 CD45RBlow CD25 cells reveals their suppressor
functions. Sort-purified CD4 CD45RBlow CD25 cells
were tested in suppression assays after 6 d culture (b) or af-
ter only 3 d exposure to LPS and anti-CD3. Suppression
by CD4 CD25 treated similarly is also shown. (c) Freshly
isolated CD4 CD25 and CD4 CD45RBlow CD25
served as control. Nomenclatures are as described in a.
Each measurement has been performed at least twice on
independent cell samples and resulted in similar curves.
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with the present observations on LPS activation of Treg
through TLR-4, it is striking that the TLR-5 receptor
binds flagellin (32), another bacterial product. Further-
more, all endogenous ligands identified to date, which in
addition to LPS, bind TLR-4 and induce signaling in vari-
ous cell types, are molecules involved in inflammatory re-
sponses. Thus, this is the case for HSP, HSP-60 (10), HSP-
70 (12), and GP96 (11), heparan sulfate (33), surfactant
protein A (34), and the product of degradation of the ex-
tracellular matrix hyaluronic acid (14). Natural ligands for
TLR-7 and TLR-8 are not yet identified, but the finding
that seven out of nine TLR molecules are expressed by
Treg suggests that a rather large universe of inflammation-
related endogenous and pathogen-associated molecules
might directly modulate their activities.
LPS effects on murine T cells have been generally inter-
preted as indirectly mediated through activation of acces-
sory cells (19, 35, 36), although sporadic evidence of direct
triggering has also been provided (37–39). The frequency
of CD4 T cells expressing TLR-4 at the cell surface could
not be assessed because the available antibodies that specif-
ically recognize the murine TLR-4–MD2 complex on
peritoneal macrophages fails to interact with both B and T
cells (40 and unpublished data). Assuming homogeneous
expression levels by positive cells, a quantitative interpreta-
tion of the present RT-PCR analyses would indicate
TLR-4 expression in, at most, some 15% of the total
CD4 compartment (10% CD25 and 1/4 of the 20%
CD45RBlow CD25). In addition, the results of LPS-stim-
ulated cell cultures suggest that only a fraction of CD4
CD45RBlow CD25/ cells respond to TLR-4 ligation,
thus being compatible with a previous report indicating
that 3% total T splenocytes are LPS responders (37). The
essential finding here, namely that all CD4 T cells that re-
spond to LPS are encompassed in the Treg subpopulation,
provides additional evidence for the evolutionary and
functional relationship between innate and adaptive im-
munity. In turn, our results may suggest that Treg belong
to a particular class of “nonclassical”  T lymphocytes,
along with NK and  T cells. Whether the selective TLR
expression by Treg described here defines a unique lineage
or a particular differentiation stage will be a crucial issue to
address in future experiments.
Several models of inflammation induced by pathogens in
immunocompromised animals have shown that Treg are
necessary to prevent deleterious immune responses (1, 2).
The process of Treg activation in these systems had not
been addressed until now. Our findings that a bacterial
product can directly activate Treg and enhance their effec-
tor functions suggest polyclonal activation of these cells
during infection. In turn, they provide the first evidence
that cells involved in the control of inflammation respond
to proinflammatory microbial molecules and add to previ-
ous reports demonstrating that Treg are particularly sensi-
tive to inflammatory chemokines (6, 7). The survival/pro-
liferative responses to LPS, TCR ligation, and IL-2 may
suggest, however, that during bacterial infection unspecific
activation of Treg through TLR is amplified by specific
recognition of antigens. Moreover, specific delayed-type
hypersensitivity and graft-versus-host reactions, as well as
graft rejection and classical immunization, have all been
shown to be down modulated or abolished by pretreatment
of mice with various doses of LPS (41–43). Activation of
Treg by LPS may well be the basis for these observations.
In the course of an infection, however, Treg activation
does not fully impair the protective response even though
it may limit its magnitude (2) and, certainly, its deleterious
pathogenic consequences for the host (1, 2). The specific
immune response to nonself antigens may take place as the
consequence of a natural ratio of regulatory to effector cells
heavily biased toward the latter and a Treg TCR repertoire
seemingly biased toward the recognition of self-antigens
(17, 44–46). Thus, presentation of nonself peptides during
acute infection is predominant, resulting in the initial pref-
erential activation of naive responder cells. As infection
regresses and pathogens are cleared, presentation of self-
ligands to Treg predominates, leading to the control of in-
flammation and preventing the activation of naive, autore-
active T cells by self-peptides presented in an inflammatory
context. Importantly, inflammatory stimuli may lead to
detrimental systemic effects and the stimulation of Treg
through TLRs, either by microbial or endogenous ligands
Figure 6. LPS-treated CD4 CD25 are efficient regulatory cells in
vivo. RAG-1–deficient animals (three per experimental group) received
105 CD4 CD45RBhigh Thy1.2 cells alone or together with the same
number of CD4 CD25 Thy1.1 cells, either freshly isolated or main-
tained in culture sequentially with LPS and IL-2 for a total of 6 d (as de-
scribed in Fig. 4). Mice were analyzed at 21 d after transfer. (a) Control of
wasting disease. The white dot represents an animal found dead on day 17
after transfer. Its weight monitored on day 16 was used. (b) Control of
lymphocyte expansion. Numbers of CD4 Thy1.2 cells (originally
CD45RBhigh) recovered in the mesenteric LNs. (c) Viability and pheno-
type of the transferred CD4 CD25 cells. Representative staining of ax-
illary LNs from recipients of cotransfers.
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released during stress or tissue damage, might be required
to prevent generalized immunopathologies.
Finally, these findings may contribute novel insights to
the cellular basis of chronic infections and to the beneficial
effect of various infections on the onset of autoimmune
diseases (47, 48).
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